Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281042 · ClinicalTrials.gov registry record
Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
A clinical trial, sponsored by Notal Vision.
- Completed
- Registry status
- 20
- Enrollment target
NCT05281042: Completed study, sponsored by Notal Vision.
NCT05281042 is a clinical trial that has completed, run by Notal Vision. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05281042 has completed, sponsored by Notal Vision.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The study will enroll up to 30 AMD patients diagnosed with NV-AMD in at least one eye at the time of enrollment. At the Study Visit, fluid must be present in at least one eye of the subjects. If only one eye qualifies for enrollment, that will be assigned as the study eye. If both eyes are eligible, the study eye will be assigned according to a randomization schedule. Only one eye of each subject will be enrolled in the study. All subjects will be enrolled at 1 site in the United States. Subjects must meet all inclusion and no exclusion criteria.
Primary Outcome
volume \[nl\] of the TRF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2022-01-05 |
What the finished NCT05281042 record still lists
NCT05281042 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05281042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05281042 about?
NCT05281042 is a clinical study titled "Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study". The study will enroll up to 30 AMD patients diagnosed with NV-AMD in at least one eye at the time of enrollment. At the Study Visit, fluid must be present in at least one eye of the subjects. If only one eye qualifies for enrollment, that will be assigned as the study eye. If both eyes are eligible,...
What is the current status of trial NCT05281042?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2021-09-13. Estimated completion is 2022-01-05.
Who is sponsoring clinical trial NCT05281042?
This trial is sponsored by Notal Vision, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI